/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/4252x1496/43d16b540f/ehra-acronym-name-rgb.png)
Dr. Vidal Essebag completed his MD, cardiology training, MSc and PhD in epidemiology and biostatistics at McGill University (Montreal, Canada). He subsequently completed a clinical and research fellowship in cardiac electrophysiology at Harvard University (Boston, United States) under Dr. Mark E. Josephson. He is Director of Cardiac Electrophysiology at the McGill University Health Centre, Professor of Medicine at McGill University, and a Clinician Scientist supported by the Canadian Institutes of Health Research (CIHR) and the Fonds de recherche du Québec - Santé (FRQS).
Dr. Essebag currently has over 190 publications in peer-reviewed journals and is a principal investigator or co-investigator in several clinical trials including ablation of atrial fibrillation and ventricular tachycardia, defibrillator and cardiac resynchronization therapy and peri-operative anticoagulation management. He has also been actively involved in national guideline committees including atrial fibrillation,
Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: a secondary analysis of the BRUISE CONTROL trial
Event: EHRA 2019
Topic: Device Complications and Lead Extraction
Session: Moderated ePosters 15: Implantable device therapy : the good, the bad and the ugly
